Molecular targets and cancer therapeutics.

A1 First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors. Jian-Ming Xu, Lin Sheng, Yan Wang, Yu-Ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Ye Hua, Wei-Guo Su. The 307th Hospital of Chinese People's Liberation Army, Beijing, China; Beijing Cancer Hospital, Beijing, China; Hutchison MediPharma Limited, Shanghai, China.